Gabapentin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Form, By Type, By Application, By Distribution Channel, By Region and Competition, 2020-2030F

Description

The Global Gabapentin Market, valued at USD 2.04 Billion in 2024, is projected to experience a CAGR of 5.60% to reach USD 2.83 Billion by 2030. Gabapentin, an anticonvulsant medication, is primarily utilized for managing neuropathic pain and as an adjunct therapy for partial seizures in epilepsy. The global market for gabapentin is significantly driven by the increasing prevalence of chronic neurological conditions, such as epilepsy and various forms of neuropathic pain, alongside the expanding geriatric population, which is more susceptible to these disorders.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.04 Billion
Market Size 2030	USD 2.83 Billion
CAGR 2025-2030	5.60%
Fastest Growing Segment	Epilepsy
Largest Market	North America

Key Market Drivers

The rising prevalence of neuropathic pain disorders significantly drives the global gabapentin market, as the medication is a primary treatment option for these conditions. Neuropathic pain, resulting from nerve damage or disease, often presents as chronic and debilitating, necessitating effective pharmaceutical interventions. According to a February 2024 article published in PubMed Central titled 'Shedding light on neuropathic pain: Current and emerging tools for diagnosis, screening, and quantification', the estimated prevalence of neuropathic pain in Europe is 7%-8%.

Key Market Challenges

Increasing regulatory scrutiny regarding gabapentin's potential for misuse, abuse, and off-label prescribing presents a significant challenge to the global market. This heightened oversight has prompted various jurisdictions to implement stricter monitoring protocols or reclassify gabapentin as a controlled substance, which directly affects its accessibility and prescription rates. Such reclassification introduces administrative complexities for healthcare providers and pharmacists, increasing the burden associated with prescribing and dispensing.

Key Market Trends

Advancements in Extended-Release Formulations are a significant factor shaping the global gabapentin market, driven by the pharmaceutical industry's focus on enhancing patient compliance and therapeutic outcomes. These innovative formulations offer advantages by reducing the frequency of dosing, which is crucial for individuals managing chronic conditions such as neuropathic pain, thereby promoting consistent medication adherence and more stable symptom control.

Key Market Players

Zydus Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Limited
Sun Pharmaceutical Industries Ltd.
Ascend Laboratories, LLC
Apotex Inc.
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma.
Amneal Pharmaceuticals LLC.
Cipla Ltd.
BP Pharmaceuticals Laboratories Company

Report Scope:

In this report, the Global Gabapentin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gabapentin Market, By Form:

Tablet
Capsule
Oral Solution

Gabapentin Market, By Type:

Generic
Branded

Gabapentin Market, By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Gabapentin Market, By Application:

Epilepsy
Neuropathic Pain
Restless Legs Syndrome
Others

Gabapentin Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gabapentin Market.

Available Customizations:

Global Gabapentin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gabapentin Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Form (Tablet, Capsule, Oral Solution)
- 5.2.2. By Type (Generic, Branded)
- 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
- 5.2.4. By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
5.3. Market Map

6. North America Gabapentin Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Form
- 6.2.2. By Type
- 6.2.3. By Distribution Channel
- 6.2.4. By Application
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Gabapentin Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Form
    - 6.3.1.2.2. By Type
    - 6.3.1.2.3. By Distribution Channel
    - 6.3.1.2.4. By Application
- 6.3.2. Canada Gabapentin Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Form
    - 6.3.2.2.2. By Type
    - 6.3.2.2.3. By Distribution Channel
    - 6.3.2.2.4. By Application
- 6.3.3. Mexico Gabapentin Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Form
    - 6.3.3.2.2. By Type
    - 6.3.3.2.3. By Distribution Channel
    - 6.3.3.2.4. By Application

7. Europe Gabapentin Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Form
- 7.2.2. By Type
- 7.2.3. By Distribution Channel
- 7.2.4. By Application
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Gabapentin Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Form
    - 7.3.1.2.2. By Type
    - 7.3.1.2.3. By Distribution Channel
    - 7.3.1.2.4. By Application
- 7.3.2. France Gabapentin Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Form
    - 7.3.2.2.2. By Type
    - 7.3.2.2.3. By Distribution Channel
    - 7.3.2.2.4. By Application
- 7.3.3. United Kingdom Gabapentin Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Form
    - 7.3.3.2.2. By Type
    - 7.3.3.2.3. By Distribution Channel
    - 7.3.3.2.4. By Application
- 7.3.4. Italy Gabapentin Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Form
    - 7.3.4.2.2. By Type
    - 7.3.4.2.3. By Distribution Channel
    - 7.3.4.2.4. By Application
- 7.3.5. Spain Gabapentin Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Form
    - 7.3.5.2.2. By Type
    - 7.3.5.2.3. By Distribution Channel
    - 7.3.5.2.4. By Application

8. Asia Pacific Gabapentin Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Form
- 8.2.2. By Type
- 8.2.3. By Distribution Channel
- 8.2.4. By Application
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Gabapentin Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Form
    - 8.3.1.2.2. By Type
    - 8.3.1.2.3. By Distribution Channel
    - 8.3.1.2.4. By Application
- 8.3.2. India Gabapentin Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Form
    - 8.3.2.2.2. By Type
    - 8.3.2.2.3. By Distribution Channel
    - 8.3.2.2.4. By Application
- 8.3.3. Japan Gabapentin Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Form
    - 8.3.3.2.2. By Type
    - 8.3.3.2.3. By Distribution Channel
    - 8.3.3.2.4. By Application
- 8.3.4. South Korea Gabapentin Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Form
    - 8.3.4.2.2. By Type
    - 8.3.4.2.3. By Distribution Channel
    - 8.3.4.2.4. By Application
- 8.3.5. Australia Gabapentin Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Form
    - 8.3.5.2.2. By Type
    - 8.3.5.2.3. By Distribution Channel
    - 8.3.5.2.4. By Application

9. Middle East & Africa Gabapentin Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Form
- 9.2.2. By Type
- 9.2.3. By Distribution Channel
- 9.2.4. By Application
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Gabapentin Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Form
    - 9.3.1.2.2. By Type
    - 9.3.1.2.3. By Distribution Channel
    - 9.3.1.2.4. By Application
- 9.3.2. UAE Gabapentin Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Form
    - 9.3.2.2.2. By Type
    - 9.3.2.2.3. By Distribution Channel
    - 9.3.2.2.4. By Application
- 9.3.3. South Africa Gabapentin Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Form
    - 9.3.3.2.2. By Type
    - 9.3.3.2.3. By Distribution Channel
    - 9.3.3.2.4. By Application

10. South America Gabapentin Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Form
- 10.2.2. By Type
- 10.2.3. By Distribution Channel
- 10.2.4. By Application
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Gabapentin Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Form
    - 10.3.1.2.2. By Type
    - 10.3.1.2.3. By Distribution Channel
    - 10.3.1.2.4. By Application
- 10.3.2. Colombia Gabapentin Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Form
    - 10.3.2.2.2. By Type
    - 10.3.2.2.3. By Distribution Channel
    - 10.3.2.2.4. By Application
- 10.3.3. Argentina Gabapentin Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Form
    - 10.3.3.2.2. By Type
    - 10.3.3.2.3. By Distribution Channel
    - 10.3.3.2.4. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Gabapentin Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Zydus Pharmaceuticals, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Glenmark Pharmaceuticals Limited
15.3. Sun Pharmaceutical Industries Ltd.
15.4. Ascend Laboratories, LLC
15.5. Apotex Inc.
15.6. Teva Pharmaceutical Industries Ltd.
15.7. Aurobindo Pharma.
15.8. Amneal Pharmaceuticals LLC.
15.9. Cipla Ltd.
15.10. BP Pharmaceuticals Laboratories Company